Information Provided By:
Fly News Breaks for July 11, 2016
JUNO, BLUE
Jul 11, 2016 | 08:29 EDT
After the FDA placed a clinical hold on Juno Therapeutics' (JUNO) JCAR015, SunTrust does not expect bluebird bio's (BLUE) CAR T program to be affected by this development. The firm says that there a number of important differences between the programs, including lower neurotoxicity among bluebird's MM patients than among Juno's ALL patients, and the much lower cyclophosphamide dose being used by bluebird. The firm keeps a Buy rating on bluebird.